Video

Jeffrey Curtis, MD, Shares COVID-19 Vaccine Recommendations for Rheumatologists

Author(s):

The Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force shares what was learned from the Omicron variant and how the recommendations for rheumatologists has been affected by it.

The American College of Rheumatology (ACR) announced its updated version of COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases earlier this month.

Jeffrey Curtis, MD, MS, Chair of the ACR COVID-19 Clinical Guidance Task Force, shared how the wave of the Omicron variant of COVID-19 has affected they way rheumatologists should continue to treat their patients and how vaccine doses are recommended for each patient population.

Some of the updates include understanding who needs additional doses and booster doses, the protocol for monoclonal antibody treatment, and treatment schedules for patients on immunosuppressant medications.

"As rheumatologists, we need to be querying patients as to how recently they were vaccinated, with what, in light of their treatments and their disease and their activity," Curtis said. "Early on, everyone was just in a hurry to get them something even if the vaccine response wasn't great."

"Now, we have a little bit more time to be thoughtful to try to get it right to the extent we know what right looks like," he continued. "So, this is where ongoing vigilance to make sure you or your office staff are screening patients as to their vaccination status. And how many doses they've gotten, of what, is going to continue to be important."

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.